The National Kidney Federation (NKF) is the largest kidney patient association in the United Kingdom. The NKF entered the United Kingdom’s renal landscape in 1979 as a national organization when renal patients realized that individual Kidney Patient Associations (KPAs) needed to band together to have their voices heard in concert. While the current 69 KPAs remain both the ears and the eyes of the NKF, end-stage renal disease (ESRD) patients or their caregivers serve as the NKF’s officers, members of its executive committee and its workforce.
Multiple Comorbidities Increases Risk of Early Dialysis Initiation
Patients who have CKD along with other comorbidities face an increased risk of early dialysis initiation, researchers found. Smoking, older age and proteinuria significantly increased the risk for two or more comorbidities. The most common comorbidities found in these patients are diabetes, hypertension and hyperlipidemia.
A working vascular access is the lifeline for a hemodialysis patient. It is also an Achilles heel, for when it fails, another access (frequently a catheter) must be quickly placed for life preserving hemodialysis to continue. While an arteriovenous fistula (a natural conduit connecting an artery and a vein) is the preferred vascular access, expanded polytetrafluoroethylene (ePTFE) synthetic grafts are frequently used as the second choice for a vascular access, before placing a catheter.
Life-threatening bleeds (LTB) from arteriovenous fistulas or grafts are significant bleeds which are not stopped by application of a normal amount of pressure as is commonly used to stop bleeding after dialysis needle removal. In many cases they occur spontaneously at home between dialysis sessions, away from the clinic or caregiving team. Although access-related LTBs are not common, they can result in the loss of the patient’s access and even be fatal.
As a healthcare professional, you know your treatment plans are only as powerful as your patients’ commitment. Your patients’ quality of life not only depends on your expertise but also on how well they implement their care plan after they leave your office. And when it comes to patients with end-stage renal disease (ESRD), non-adherence to dialysis and supporting factors such as diet and medication can lead to severe complications and an increased risk of mortality. Unfortunately, at least 50 % of hemodialysis patients are believed to be non-adherent, according to a study by the Department of Internal Medicine at Cairo University.
In February, the Bipartisan Budget Act of 2018 was signed into law, expanding Medicare reimbursement for a small list of telehealth services, including home dialysis for end-stage renal disease (ESRD), according to the Clinical Journal of American Society of Nephrology.
Clotting and bleeding are major causes of mortality and morbidity during high risk ECMO therapy that treats the “sickest of the sick” by infusing patients with oxygen-rich blood drawn from an ECMO circuit. One key component of an ECMO circuit is the oxygenator. As a clot develops in the oxygenator over time, the volume of oxygenated blood decreases and less oxygen-rich blood is delivered to the critically ill patient. If the clot gets large enough, the oxygenator will need to be switched out by the perfusionist as quickly as possible and replaced by one that will continue to oxygenate the blood.
One of the most devastating hurricanes in the history of the United States, Hurricane Katrina caused $75 billion in damage in New Orleans and along the Mississippi coast. Beyond its toll on infrastructure and the lives of the area’s citizens, the hurricane exposed several gaps in emergency preparedness for hemodialysis patients. Many clinics in the area didn’t have sufficient emergency preparedness plans in place; patients didn’t know how to adequately prepare for the storm; and public health officials were unaware of how much of the population was dependent on dialysis.
Otsuka Acquires Visterra
Otsuka has acquired antibody therapy maker Visterra for $430 million. Otsuka hopes to take advantages of Visterra’s therapies for CKD and other conditions.
DaVita Profits Decline 15 Percent for Q3
The loss can be attributed to higher than expected medical costs and the underperforming managed care business. Net loss for the quarter was $214 million. As of the end of September, DaVita provided services to 218,200 patients.